BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kovalchuk O, Filkowski J, Meservy J, Ilnytskyy Y, Tryndyak VP, Chekhun VF, Pogribny IP. Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther. 2008;7:2152-2159. [PMID: 18645025 DOI: 10.1158/1535-7163.mct-08-0021] [Cited by in Crossref: 454] [Cited by in F6Publishing: 214] [Article Influence: 32.4] [Reference Citation Analysis]
Number Citing Articles
1 Parafioriti A, Cifola I, Gissi C, Pinatel E, Vilardo L, Armiraglio E, Di Bernardo A, Daolio PA, Felsani A, D'Agnano I, Berardi AC. Expression profiling of microRNAs and isomiRs in conventional central chondrosarcoma. Cell Death Discov 2020;6:46. [PMID: 32566253 DOI: 10.1038/s41420-020-0282-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
2 Hamidi AA, Zangoue M, Kashani D, Zangouei AS, Rahimi HR, Abbaszadegan MR, Moghbeli M. MicroRNA-217: a therapeutic and diagnostic tumor marker. Expert Rev Mol Diagn 2021;:1-16. [PMID: 34883033 DOI: 10.1080/14737159.2022.2017284] [Reference Citation Analysis]
3 Saito J, Hirota T, Furuta S, Kobayashi D, Takane H, Ieiri I. Association between DNA methylation in the miR-328 5'-flanking region and inter-individual differences in miR-328 and BCRP expression in human placenta. PLoS One 2013;8:e72906. [PMID: 23991164 DOI: 10.1371/journal.pone.0072906] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
4 Wang PY, Li YJ, Zhang S, Li ZL, Yue Z, Xie N, Xie SY. Regulating A549 cells growth by ASO inhibiting miRNA expression. Mol Cell Biochem 2010;339:163-71. [PMID: 20049626 DOI: 10.1007/s11010-009-0380-2] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 2.8] [Reference Citation Analysis]
5 Dobre EG, Dinescu S, Costache M. Connecting the Missing Dots: ncRNAs as Critical Regulators of Therapeutic Susceptibility in Breast Cancer. Cancers (Basel) 2020;12:E2698. [PMID: 32967267 DOI: 10.3390/cancers12092698] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
6 Donzelli S, Mori F, Biagioni F, Bellissimo T, Pulito C, Muti P, Strano S, Blandino G. MicroRNAs: short non-coding players in cancer chemoresistance. Mol Cell Ther 2014;2:16. [PMID: 26056584 DOI: 10.1186/2052-8426-2-16] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
7 Zhu W, Liu M, Fan Y, Ma F, Xu N, Xu B. Dynamics of circulating microRNAs as a novel indicator of clinical response to neoadjuvant chemotherapy in breast cancer. Cancer Med 2018;7:4420-33. [PMID: 30099860 DOI: 10.1002/cam4.1723] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
8 Huang JY, Zhang K, Chen DQ, Chen J, Feng B, Song H, Chen Y, Zhu Z, Lu L, De W. MicroRNA-451: epithelial-mesenchymal transition inhibitor and prognostic biomarker of hepatocelluar carcinoma. Oncotarget. 2015;6:18613-18630. [PMID: 26164082 DOI: 10.18632/oncotarget.4317] [Cited by in Crossref: 44] [Cited by in F6Publishing: 52] [Article Influence: 7.3] [Reference Citation Analysis]
9 Redis RS, Berindan-Neagoe I, Pop VI, Calin GA. Non-coding RNAs as theranostics in human cancers. J Cell Biochem. 2012;113:1451-1459. [PMID: 22213511 DOI: 10.1002/jcb.24038] [Cited by in Crossref: 16] [Cited by in F6Publishing: 30] [Article Influence: 1.6] [Reference Citation Analysis]
10 Carta A, Chetcuti R, Ayers D. An Introspective Update on the Influence of miRNAs in Breast Carcinoma and Neuroblastoma Chemoresistance. Genet Res Int 2014;2014:743050. [PMID: 25548681 DOI: 10.1155/2014/743050] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
11 Tomiyasu H, Tsujimoto H. Comparative Aspects of Molecular Mechanisms of Drug Resistance through ABC Transporters and Other Related Molecules in Canine Lymphoma. Vet Sci 2015;2:185-205. [PMID: 29061940 DOI: 10.3390/vetsci2030185] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
12 Liu K, Qian T, Tang L, Wang J, Yang H, Ren J. Decreased expression of microRNA let-7i and its association with chemotherapeutic response in human gastric cancer. World J Surg Oncol. 2012;10:225. [PMID: 23107361 DOI: 10.1186/1477-7819-10-225] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 3.5] [Reference Citation Analysis]
13 Liang Z, Li Y, Huang K, Wagar N, Shim H. Regulation of miR-19 to breast cancer chemoresistance through targeting PTEN. Pharm Res. 2011;28:3091-3100. [PMID: 21853360 DOI: 10.1007/s11095-011-0570-y] [Cited by in Crossref: 81] [Cited by in F6Publishing: 83] [Article Influence: 7.4] [Reference Citation Analysis]
14 Wang H, Tan G, Dong L, Cheng L, Li K, Wang Z, Luo H. Circulating MiR-125b as a marker predicting chemoresistance in breast cancer. PLoS One. 2012;7:e34210. [PMID: 22523546 DOI: 10.1371/journal.pone.0034210] [Cited by in Crossref: 169] [Cited by in F6Publishing: 165] [Article Influence: 16.9] [Reference Citation Analysis]
15 Wang Y, Zhou P, Li P, Yang F, Gao XQ. Long non-coding RNA H19 regulates proliferation and doxorubicin resistance in MCF-7 cells by targeting PARP1. Bioengineered 2020;11:536-46. [PMID: 32345117 DOI: 10.1080/21655979.2020.1761512] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
16 Anuj, Arivazhagan L, Venkatraman G, Rayala SK. Increased Expression of MicroRNA 551a by c-Fos Reduces Focal Adhesion Kinase Levels and Blocks Tumorigenesis. Mol Cell Biol 2019;39:e00577-18. [PMID: 30670568 DOI: 10.1128/MCB.00577-18] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
17 Lenkala D, Gamazon ER, LaCroix B, Im HK, Huang RS. MicroRNA biogenesis and cellular proliferation. Transl Res 2015;166:145-51. [PMID: 25724890 DOI: 10.1016/j.trsl.2015.01.012] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
18 Shevde LA, Metge BJ, Mitra A, Xi Y, Ju J, King JA, Samant RS. Spheroid-forming subpopulation of breast cancer cells demonstrates vasculogenic mimicry via hsa-miR-299-5p regulated de novo expression of osteopontin. J Cell Mol Med 2010;14:1693-706. [PMID: 19538464 DOI: 10.1111/j.1582-4934.2009.00821.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 39] [Article Influence: 2.4] [Reference Citation Analysis]
19 Zhou N, Qu Y, Xu C, Tang Y. Upregulation of microRNA-375 increases the cisplatin-sensitivity of human gastric cancer cells by regulating ERBB2. Exp Ther Med. 2016;11:625-630. [PMID: 26893657 DOI: 10.3892/etm.2015.2920] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
20 Liang Z, Ahn J, Guo D, Votaw JR, Shim H. MicroRNA-302 replacement therapy sensitizes breast cancer cells to ionizing radiation. Pharm Res. 2013;30:1008-1016. [PMID: 23184229 DOI: 10.1007/s11095-012-0936-9] [Cited by in Crossref: 61] [Cited by in F6Publishing: 56] [Article Influence: 6.1] [Reference Citation Analysis]
21 Feng DD, Zhang H, Zhang P, Zheng YS, Zhang XJ, Han BW, Luo XQ, Xu L, Zhou H, Qu LH, Chen YQ. Down-regulated miR-331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukaemia. J Cell Mol Med. 2011;15:2164-2175. [PMID: 21070600 DOI: 10.1111/j.1582-4934.2010.01213.x] [Cited by in Crossref: 113] [Cited by in F6Publishing: 110] [Article Influence: 11.3] [Reference Citation Analysis]
22 He Y, Chevillet JR, Liu G, Kim TK, Wang K. The effects of microRNA on the absorption, distribution, metabolism and excretion of drugs. Br J Pharmacol 2015;172:2733-47. [PMID: 25296724 DOI: 10.1111/bph.12968] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
23 Yu AM, Pan YZ. Noncoding microRNAs: small RNAs play a big role in regulation of ADME? Acta Pharm Sin B 2012;2:93-101. [PMID: 32154096 DOI: 10.1016/j.apsb.2012.02.011] [Cited by in Crossref: 34] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
24 Zhang G, Zheng D, Chen X, Li L, Yu J. miR-152-mediated MKK7 downregulation is attenuated by MYCNOS in ovarian adenocarcinoma. Oncol Lett 2021;22:841. [PMID: 34733360 DOI: 10.3892/ol.2021.13102] [Reference Citation Analysis]
25 Schuetz TA, Becker S, Mang A, Toma A, Buzug TM. Modelling of glioblastoma growth by linking a molecular interaction network with an agent-based model. Mathematical and Computer Modelling of Dynamical Systems 2013;19:417-33. [DOI: 10.1080/13873954.2013.777748] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
26 An X, Sarmiento C, Tan T, Zhu H. Regulation of multidrug resistance by microRNAs in anti-cancer therapy. Acta Pharm Sin B 2017;7:38-51. [PMID: 28119807 DOI: 10.1016/j.apsb.2016.09.002] [Cited by in Crossref: 88] [Cited by in F6Publishing: 92] [Article Influence: 14.7] [Reference Citation Analysis]
27 Ge C, Cao B, Feng D, Zhou F, Zhang J, Yang N, Feng S, Wang G, Aa J. The down-regulation of SLC7A11 enhances ROS induced P-gp over-expression and drug resistance in MCF-7 breast cancer cells. Sci Rep 2017;7:3791. [PMID: 28630426 DOI: 10.1038/s41598-017-03881-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
28 Uribe JH, Collado-Romero M, Zaldívar-López S, Arce C, Bautista R, Carvajal A, Cirera S, Claros MG, Garrido JJ. Transcriptional analysis of porcine intestinal mucosa infected with Salmonella Typhimurium revealed a massive inflammatory response and disruption of bile acid absorption in ileum. Vet Res 2016;47:11. [PMID: 26738723 DOI: 10.1186/s13567-015-0286-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
29 Szkolnicka D, Lucendo-Villarin B, Moore JK, Simpson KJ, Forbes SJ, Hay DC. Reducing Hepatocyte Injury and Necrosis in Response to Paracetamol Using Noncoding RNAs. Stem Cells Transl Med 2016;5:764-72. [PMID: 27057006 DOI: 10.5966/sctm.2015-0117] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
30 Srivastava SK, Arora S, Averett C, Singh S, Singh AP. Modulation of microRNAs by phytochemicals in cancer: underlying mechanisms and translational significance. Biomed Res Int 2015;2015:848710. [PMID: 25853141 DOI: 10.1155/2015/848710] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 4.6] [Reference Citation Analysis]
31 Zhao Y, Chen J, Wei W, Qi X, Li C, Ren J. The dual-inhibitory effect of miR-338-5p on the multidrug resistance and cell growth of hepatocellular carcinoma. Signal Transduct Target Ther 2018;3:3. [PMID: 29527329 DOI: 10.1038/s41392-017-0003-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
32 Jia R, Wang C. MiR-29b-3p Reverses Cisplatin Resistance by Targeting COL1A1 in Non-Small-Cell Lung Cancer A549/DDP Cells. Cancer Manag Res 2020;12:2559-66. [PMID: 32368137 DOI: 10.2147/CMAR.S246625] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
33 Hummel R, Watson DI, Smith C, Kist J, Michael MZ, Haier J, Hussey DJ. Mir-148a improves response to chemotherapy in sensitive and resistant oesophageal adenocarcinoma and squamous cell carcinoma cells. J Gastrointest Surg. 2011;15:429-438. [PMID: 21246413 DOI: 10.1007/s11605-011-1418-9] [Cited by in Crossref: 66] [Cited by in F6Publishing: 64] [Article Influence: 6.0] [Reference Citation Analysis]
34 Gu X, Li JY, Guo J, Li PS, Zhang WH. Influence of MiR-451 on Drug Resistances of Paclitaxel-Resistant Breast Cancer Cell Line. Med Sci Monit 2015;21:3291-7. [PMID: 26516138 DOI: 10.12659/msm.894475] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
35 Rigalli JP, Ciriaci N, Arias A, Ceballos MP, Villanueva SS, Luquita MG, Mottino AD, Ghanem CI, Catania VA, Ruiz ML. Regulation of multidrug resistance proteins by genistein in a hepatocarcinoma cell line: impact on sorafenib cytotoxicity. PLoS One 2015;10:e0119502. [PMID: 25781341 DOI: 10.1371/journal.pone.0119502] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 6.4] [Reference Citation Analysis]
36 Petrović N, Nakashidze I, Nedeljković M. Breast Cancer Response to Therapy: Can microRNAs Lead the Way? J Mammary Gland Biol Neoplasia 2021;26:157-78. [PMID: 33479880 DOI: 10.1007/s10911-021-09478-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
37 Nordentoft I, Birkenkamp-Demtroder K, Agerbæk M, Theodorescu D, Ostenfeld MS, Hartmann A, Borre M, Ørntoft TF, Dyrskjøt L. miRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer. BMC Med Genomics 2012;5:40. [PMID: 22954303 DOI: 10.1186/1755-8794-5-40] [Cited by in Crossref: 65] [Cited by in F6Publishing: 62] [Article Influence: 6.5] [Reference Citation Analysis]
38 Garrido-Cano I, Pattanayak B, Adam-Artigues A, Lameirinhas A, Torres-Ruiz S, Tormo E, Cervera R, Eroles P. MicroRNAs as a clue to overcome breast cancer treatment resistance. Cancer Metastasis Rev 2021. [PMID: 34524579 DOI: 10.1007/s10555-021-09992-0] [Reference Citation Analysis]
39 Luzhna L, Filkowski J, Kovalchuk O. High and low dose radiation effects on mammary adenocarcinoma cells - an epigenetic connection. Oncoscience 2016;3:88-97. [PMID: 27226982 DOI: 10.18632/oncoscience.298] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
40 Mei Y, Gao C, Wang K, Cui L, Li W, Zhao X, Liu F, Wu M, Deng G, Ding W, Jia H, Li Z. Effect of microRNA-210 on prognosis and response to chemotherapeutic drugs in pediatric acute lymphoblastic leukemia. Cancer Sci 2014;105:463-72. [PMID: 24720529 DOI: 10.1111/cas.12370] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 4.8] [Reference Citation Analysis]
41 Chandhok NS, Prebet T. Insights into novel emerging epigenetic drugs in myeloid malignancies. Ther Adv Hematol 2019;10:2040620719866081. [PMID: 31431820 DOI: 10.1177/2040620719866081] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
42 Luo H, Cong S, Dong J, Jin L, Jiang D, Wang X, Chen Q, Li F. Paired‑related homeobox 1 overexpression promotes multidrug resistance via PTEN/PI3K/AKT signaling in MCF‑7 breast cancer cells. Mol Med Rep 2020;22:3183-90. [PMID: 32945446 DOI: 10.3892/mmr.2020.11414] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
43 Ma L, Ma S, Zhao G, Yang L, Zhang P, Yi Q, Cheng S. miR-708/LSD1 axis regulates the proliferation and invasion of breast cancer cells. Cancer Med 2016;5:684-92. [PMID: 26833707 DOI: 10.1002/cam4.623] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
44 Wang J, Li Y, Dong X, Wang Y, Chong X, Yu T, Zhang F, Chen D, Zhang L, Gao J, Yang C, Han J, Li W. A Micelle Self-Assembled from Doxorubicin-Arabinoxylan Conjugates with pH-Cleavable Bond for Synergistic Antitumor Therapy. Nanoscale Res Lett 2017;12:73. [PMID: 28124299 DOI: 10.1186/s11671-017-1836-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
45 Zhang JT, Chen J, Ruan HC, Li FX, Pang S, Xu YJ, Huang DL, Wu XH. Microribonucleic Acid-15a-5p Alters Adriamycin Resistance in Breast Cancer Cells by Targeting Cell Division Cycle-Associated Protein 4. Cancer Manag Res 2021;13:8425-34. [PMID: 34785950 DOI: 10.2147/CMAR.S333830] [Reference Citation Analysis]
46 Sousa D, Matthiesen R, Lima RT, Vasconcelos MH. Deep Sequencing Analysis Reveals Distinctive Non-Coding RNAs When Comparing Tumor Multidrug-Resistant Cells and Extracellular Vesicles with Drug-Sensitive Counterparts. Cancers (Basel) 2020;12:E200. [PMID: 31947507 DOI: 10.3390/cancers12010200] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
47 Cesi G, Walbrecq G, Margue C, Kreis S. Transferring intercellular signals and traits between cancer cells: extracellular vesicles as "homing pigeons". Cell Commun Signal 2016;14:13. [PMID: 27282631 DOI: 10.1186/s12964-016-0136-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
48 Xu Y, Ohms SJ, Li Z, Wang Q, Gong G, Hu Y, Mao Z, Shannon MF, Fan JY. Changes in the expression of miR-381 and miR-495 are inversely associated with the expression of the MDR1 gene and development of multi-drug resistance. PLoS One 2013;8:e82062. [PMID: 24303078 DOI: 10.1371/journal.pone.0082062] [Cited by in Crossref: 55] [Cited by in F6Publishing: 60] [Article Influence: 6.1] [Reference Citation Analysis]
49 Dettmer M, Perren A, Moch H, Komminoth P, Nikiforov YE, Nikiforova MN. Comprehensive MicroRNA expression profiling identifies novel markers in follicular variant of papillary thyroid carcinoma. Thyroid 2013;23:1383-9. [PMID: 23427895 DOI: 10.1089/thy.2012.0632] [Cited by in Crossref: 92] [Cited by in F6Publishing: 75] [Article Influence: 10.2] [Reference Citation Analysis]
50 Yuan J, Lang J, Liu C, Zhou K, Chen L, Liu Y. The expression and function of miRNA-451 in osteosarcoma. Med Oncol 2015;32:324. [PMID: 25471786 DOI: 10.1007/s12032-014-0324-x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 3.0] [Reference Citation Analysis]
51 Kopp F, Oak PS, Wagner E, Roidl A. miR-200c sensitizes breast cancer cells to doxorubicin treatment by decreasing TrkB and Bmi1 expression. PLoS One 2012;7:e50469. [PMID: 23209748 DOI: 10.1371/journal.pone.0050469] [Cited by in Crossref: 76] [Cited by in F6Publishing: 69] [Article Influence: 7.6] [Reference Citation Analysis]
52 Motamedi M, Hashemzadeh Chaleshtori M, Ghasemi S, Mokarian F. Plasma Level Of miR-21 And miR-451 In Primary And Recurrent Breast Cancer Patients. Breast Cancer (Dove Med Press) 2019;11:293-301. [PMID: 31749630 DOI: 10.2147/BCTT.S224333] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
53 Krishnan P, Ghosh S, Wang B, Heyns M, Li D, Mackey JR, Kovalchuk O, Damaraju S. Genome-wide profiling of transfer RNAs and their role as novel prognostic markers for breast cancer. Sci Rep 2016;6:32843. [PMID: 27604545 DOI: 10.1038/srep32843] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
54 Matuszcak C, Haier J, Hummel R, Lindner K. MicroRNAs: Promising chemoresistance biomarkers in gastric cancer with diagnostic and therapeutic potential. World J Gastroenterol 2014; 20(38): 13658-13666 [PMID: 25320504 DOI: 10.3748/wjg.v20.i38.13658] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
55 Hsieh MJ, Lin CW, Su SC, Reiter RJ, Chen AW, Chen MK, Yang SF. Effects of miR-34b/miR-892a Upregulation and Inhibition of ABCB1/ABCB4 on Melatonin-Induced Apoptosis in VCR-Resistant Oral Cancer Cells. Mol Ther Nucleic Acids 2020;19:877-89. [PMID: 31982774 DOI: 10.1016/j.omtn.2019.12.022] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 10.0] [Reference Citation Analysis]
56 Kurokawa K, Tanahashi T, Iima T, Yamamoto Y, Akaike Y, Nishida K, Masuda K, Kuwano Y, Murakami Y, Fukushima M. Role of miR-19b and its target mRNAs in 5-fluorouracil resistance in colon cancer cells. J Gastroenterol. 2012;47:883-895. [PMID: 22382630 DOI: 10.1007/s00535-012-0547-6] [Cited by in Crossref: 64] [Cited by in F6Publishing: 69] [Article Influence: 6.4] [Reference Citation Analysis]
57 Biersack B. Interplay of non-coding RNAs and approved antimetabolites such as gemcitabine and pemetrexed in mesothelioma. Noncoding RNA Res 2018;3:213-25. [PMID: 30809600 DOI: 10.1016/j.ncrna.2018.11.001] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
58 Witt KL, Moorman PG, Kovalchuk O, Holland N, Block G, Andreassen PR. Genetics and women's health issues--the commitment of EMS to women scientists and gender-associated disease topics. Environ Mol Mutagen 2010;51:774-80. [PMID: 20740639 DOI: 10.1002/em.20607] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
59 Ouyang M, Li Y, Ye S, Ma J, Lu L, Lv W, Chang G, Li X, Li Q, Wang S. MicroRNA profiling implies new markers of chemoresistance of triple-negative breast cancer. PLoS One. 2014;9:e96228. [PMID: 24788655 DOI: 10.1371/journal.pone.0096228] [Cited by in Crossref: 113] [Cited by in F6Publishing: 121] [Article Influence: 14.1] [Reference Citation Analysis]
60 Geller JI, Roth JJ, Biegel JA. Biology and Treatment of Rhabdoid Tumor. Crit Rev Oncog 2015;20:199-216. [PMID: 26349416 DOI: 10.1615/critrevoncog.2015013566] [Cited by in Crossref: 48] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
61 Humphries B, Yang C. The microRNA-200 family: small molecules with novel roles in cancer development, progression and therapy. Oncotarget 2015;6:6472-98. [PMID: 25762624 DOI: 10.18632/oncotarget.3052] [Cited by in Crossref: 183] [Cited by in F6Publishing: 195] [Article Influence: 30.5] [Reference Citation Analysis]
62 Suzuki HI, Miyazono K. Dynamics of microRNA biogenesis: crosstalk between p53 network and microRNA processing pathway. J Mol Med (Berl) 2010;88:1085-94. [PMID: 20614100 DOI: 10.1007/s00109-010-0650-1] [Cited by in Crossref: 61] [Cited by in F6Publishing: 57] [Article Influence: 5.1] [Reference Citation Analysis]
63 Bian HB, Pan X, Yang JS, Wang ZX, De W. Upregulation of microRNA-451 increases cisplatin sensitivity of non-small cell lung cancer cell line (A549). J Exp Clin Cancer Res. 2011;30:20. [PMID: 21329503 DOI: 10.1186/1756-9966-30-20] [Cited by in Crossref: 104] [Cited by in F6Publishing: 104] [Article Influence: 9.5] [Reference Citation Analysis]
64 Iorio MV, Croce CM. Causes and consequences of microRNA dysregulation. Cancer J. 2012;18:215-222. [PMID: 22647357 DOI: 10.1097/ppo.0b013e318250c001] [Cited by in Crossref: 186] [Cited by in F6Publishing: 112] [Article Influence: 18.6] [Reference Citation Analysis]
65 Yang X, He XQ, Li GD, Xu YQ. AntagomiR-451 inhibits oxygen glucose deprivation (OGD)-induced HUVEC necrosis via activating AMPK signaling. PLoS One 2017;12:e0175507. [PMID: 28445531 DOI: 10.1371/journal.pone.0175507] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
66 Zhang T, Sun Q, Liu T, Chen J, Du S, Ren C, Liao G, Yuan Y. MiR-451 increases radiosensitivity of nasopharyngeal carcinoma cells by targeting ras-related protein 14 (RAB14). Tumour Biol 2014;35:12593-9. [PMID: 25201065 DOI: 10.1007/s13277-014-2581-x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
67 Yin W, Wang P, Wang X, Song W, Cui X, Yu H, Zhu W. Identification of microRNAs and mRNAs associated with multidrug resistance of human laryngeal cancer Hep-2 cells. Braz J Med Biol Res 2013;46:546-54. [PMID: 23780424 DOI: 10.1590/1414-431X20131662] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
68 Liu H. MicroRNAs in breast cancer initiation and progression. Cell Mol Life Sci 2012;69:3587-99. [PMID: 22926415 DOI: 10.1007/s00018-012-1128-9] [Cited by in Crossref: 53] [Cited by in F6Publishing: 44] [Article Influence: 5.3] [Reference Citation Analysis]
69 Kurozumi S, Yamaguchi Y, Kurosumi M, Ohira M, Matsumoto H, Horiguchi J. Recent trends in microRNA research into breast cancer with particular focus on the associations between microRNAs and intrinsic subtypes. J Hum Genet 2017;62:15-24. [PMID: 27439682 DOI: 10.1038/jhg.2016.89] [Cited by in Crossref: 77] [Cited by in F6Publishing: 77] [Article Influence: 12.8] [Reference Citation Analysis]
70 Núñez-Acuña G, Valenzuela-Muñoz V, Valenzuela-Miranda D, Gallardo-Escárate C. Comprehensive Transcriptome Analyses in Sea Louse Reveal Novel Delousing Drug Responses Through MicroRNA regulation. Mar Biotechnol (NY) 2021;23:710-23. [PMID: 34564738 DOI: 10.1007/s10126-021-10058-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
71 Li F, Mahato RI. MicroRNAs and drug resistance in prostate cancers. Mol Pharm 2014;11:2539-52. [PMID: 24742219 DOI: 10.1021/mp500099g] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 5.0] [Reference Citation Analysis]
72 Lin G, Xu K. [Advances in tumor chemo-resistance regulated by MicroRNA]. Zhongguo Fei Ai Za Zhi 2014;17:741-9. [PMID: 25342041 DOI: 10.3779/j.issn.1009-3419.2014.10.06] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
73 Bonnet E, Michoel T, Van de Peer Y. Prediction of a gene regulatory network linked to prostate cancer from gene expression, microRNA and clinical data. Bioinformatics 2010;26:i638-44. [PMID: 20823333 DOI: 10.1093/bioinformatics/btq395] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
74 Yang JM, Jang JY, Jeon YK, Paik JH. Clinicopathologic implication of microRNA-197 in diffuse large B cell lymphoma. J Transl Med. 2018;16:162. [PMID: 29890998 DOI: 10.1186/s12967-018-1537-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
75 Rodrigues AC, Neri EA, Veríssimo-Filho S, Rebouças NA, Hirata RD, Yu AM. Atorvastatin attenuation of ABCB1 expression is mediated by microRNA miR-491-3p in Caco-2 cells. Eur J Pharm Sci 2016;93:431-6. [PMID: 27575876 DOI: 10.1016/j.ejps.2016.08.044] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
76 Hui B, Chen X, Hui L, Xi R, Zhang X. Serum miRNA expression in patients with esophageal squamous cell carcinoma. Oncol Lett 2015;10:3008-12. [PMID: 26722280 DOI: 10.3892/ol.2015.3642] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
77 Campos-Parra AD, Mitznahuatl GC, Pedroza-Torres A, Romo RV, Reyes FIP, López-Urrutia E, Pérez-Plasencia C. Micro-RNAs as Potential Predictors of Response to Breast Cancer Systemic Therapy: Future Clinical Implications. Int J Mol Sci 2017;18:E1182. [PMID: 28574440 DOI: 10.3390/ijms18061182] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
78 Kutanzi KR, Yurchenko OV, Beland FA, Checkhun VF, Pogribny IP. MicroRNA-mediated drug resistance in breast cancer. Clin Epigenetics 2011;2:171-85. [PMID: 21949547 DOI: 10.1007/s13148-011-0040-8] [Cited by in Crossref: 112] [Cited by in F6Publishing: 99] [Article Influence: 10.2] [Reference Citation Analysis]
79 Li L, Gao R, Yu Y, Kaul Z, Wang J, Kalra RS, Zhang Z, Kaul SC, Wadhwa R. Tumor suppressor activity of miR-451: Identification of CARF as a new target. Sci Rep 2018;8:375. [PMID: 29321561 DOI: 10.1038/s41598-017-18559-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
80 Pan YZ, Gao W, Yu AM. MicroRNAs regulate CYP3A4 expression via direct and indirect targeting. Drug Metab Dispos 2009;37:2112-7. [PMID: 19581388 DOI: 10.1124/dmd.109.027680] [Cited by in Crossref: 174] [Cited by in F6Publishing: 165] [Article Influence: 13.4] [Reference Citation Analysis]
81 Wang H, Guo M, Ding D, Yang F, Chen Z. Long Non-Coding RNA NNT-AS1 Contributes to Cisplatin Resistance via miR-1236-3p/ATG7 Axis in Lung Cancer Cells. Onco Targets Ther 2020;13:3641-52. [PMID: 32431515 DOI: 10.2147/OTT.S237576] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
82 Zou Z, Zou R, Zong D, Shi Y, Chen J, Huang J, Zhu J, Chen L, Bao X, Liu Y, Liu W, Huang W, Hu J, Chen Z, Lao X, Chen C, Huang X, Lu Y, Ni X, Fang D, Wu D, Lu S, Jiang M, Qiu C, Wu Y, Qiu Q, Dong Y, Su Y, Zhao C, Zhong Z, Cai J, Liang Y. miR-495 sensitizes MDR cancer cells to the combination of doxorubicin and taxol by inhibiting MDR1 expression. J Cell Mol Med. 2017;21:1929-1943. [PMID: 28411377 DOI: 10.1111/jcmm.13114] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
83 Liang Z, Feng A, Shim H. MicroRNA-30c-regulated HDAC9 mediates chemoresistance of breast cancer. Cancer Chemother Pharmacol 2020;85:413-23. [PMID: 31907648 DOI: 10.1007/s00280-019-04024-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
84 Pan YZ, Zhou A, Hu Z, Yu AM. Small nucleolar RNA-derived microRNA hsa-miR-1291 modulates cellular drug disposition through direct targeting of ABC transporter ABCC1. Drug Metab Dispos 2013;41:1744-51. [PMID: 23686318 DOI: 10.1124/dmd.113.052092] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 5.6] [Reference Citation Analysis]
85 Chen X, Wang YW, Gao P. SPIN1, negatively regulated by miR-148/152, enhances Adriamycin resistance via upregulating drug metabolizing enzymes and transporter in breast cancer. J Exp Clin Cancer Res 2018;37:100. [PMID: 29743122 DOI: 10.1186/s13046-018-0748-9] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 6.3] [Reference Citation Analysis]
86 Masri S, Phung S, Wang X, Chen S. Molecular characterization of aromatase inhibitor-resistant, tamoxifen-resistant and LTEDaro cell lines. J Steroid Biochem Mol Biol 2010;118:277-82. [PMID: 19897035 DOI: 10.1016/j.jsbmb.2009.10.011] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
87 Wei K, Wu L, Chen Y, Lin Y, Wang Y, Liu X, Xie D. Argonaute protein as a linker to command center of physiological processes. Chin J Cancer Res 2013;25:430-41. [PMID: 23997530 DOI: 10.3978/j.issn.1000-9604.2013.08.13] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
88 Gallopin M, Rau A, Jaffrézic F. A hierarchical poisson log-normal model for network inference from RNA sequencing data. PLoS One 2013;8:e77503. [PMID: 24147011 DOI: 10.1371/journal.pone.0077503] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
89 Hu Y, Qiu Y, Yagüe E, Ji W, Liu J, Zhang J. miRNA-205 targets VEGFA and FGF2 and regulates resistance to chemotherapeutics in breast cancer. Cell Death Dis 2016;7:e2291. [PMID: 27362808 DOI: 10.1038/cddis.2016.194] [Cited by in Crossref: 54] [Cited by in F6Publishing: 63] [Article Influence: 9.0] [Reference Citation Analysis]
90 Casey MC, Sweeney KJ, Brown JA, Kerin MJ. Exploring circulating micro-RNA in the neoadjuvant treatment of breast cancer. Int J Cancer 2016;139:12-22. [PMID: 26756433 DOI: 10.1002/ijc.29985] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
91 Choromańska A, Chwiłkowska A, Kulbacka J, Baczyńska D, Rembiałkowska N, Szewczyk A, Michel O, Gajewska-Naryniecka A, Przystupski D, Saczko J. Modifications of Plasma Membrane Organization in Cancer Cells for Targeted Therapy. Molecules 2021;26:1850. [PMID: 33806009 DOI: 10.3390/molecules26071850] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
92 Yu AM, Tian Y, Tu MJ, Ho PY, Jilek JL. MicroRNA Pharmacoepigenetics: Posttranscriptional Regulation Mechanisms behind Variable Drug Disposition and Strategy to Develop More Effective Therapy. Drug Metab Dispos 2016;44:308-19. [PMID: 26566807 DOI: 10.1124/dmd.115.067470] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 5.6] [Reference Citation Analysis]
93 Samadi P, Saki S, Dermani FK, Pourjafar M, Saidijam M. Emerging ways to treat breast cancer: will promises be met? Cell Oncol (Dordr) 2018;41:605-21. [PMID: 30259416 DOI: 10.1007/s13402-018-0409-1] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 6.8] [Reference Citation Analysis]
94 Li H, Yang BB. Friend or foe: the role of microRNA in chemotherapy resistance. Acta Pharmacol Sin 2013;34:870-9. [PMID: 23624759 DOI: 10.1038/aps.2013.35] [Cited by in Crossref: 63] [Cited by in F6Publishing: 66] [Article Influence: 7.0] [Reference Citation Analysis]
95 Takahashi RU, Miyazaki H, Ochiya T. The Roles of MicroRNAs in Breast Cancer. Cancers (Basel). 2015;7:598-616. [PMID: 25860815 DOI: 10.3390/cancers7020598] [Cited by in Crossref: 87] [Cited by in F6Publishing: 79] [Article Influence: 12.4] [Reference Citation Analysis]
96 Shao L, He Q, Liu Y, Liu X, Zheng J, Ma J, Liu L, Li H, Li Z, Xue Y. UPF1 regulates the malignant biological behaviors of glioblastoma cells via enhancing the stability of Linc-00313. Cell Death Dis 2019;10:629. [PMID: 31427569 DOI: 10.1038/s41419-019-1845-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
97 Yu D, dos Santos CO, Zhao G, Jiang J, Amigo JD, Khandros E, Dore LC, Yao Y, D'Souza J, Zhang Z. miR-451 protects against erythroid oxidant stress by repressing 14-3-3zeta. Genes Dev. 2010;24:1620-1633. [PMID: 20679398 DOI: 10.1101/gad.1942110] [Cited by in Crossref: 147] [Cited by in F6Publishing: 149] [Article Influence: 12.3] [Reference Citation Analysis]
98 Shah NR, Chen H. MicroRNAs in pathogenesis of breast cancer: Implications in diagnosis and treatment. World J Clin Oncol 2014; 5(2): 48-60 [PMID: 24829851 DOI: 10.5306/wjco.v5.i2.48] [Cited by in CrossRef: 42] [Cited by in F6Publishing: 39] [Article Influence: 5.3] [Reference Citation Analysis]
99 Duru N, Gernapudi R, Eades G, Eckert R, Zhou Q. Epigenetic Regulation of miRNAs and Breast Cancer Stem Cells. Curr Pharmacol Rep 2015;1:161-9. [PMID: 26052481 DOI: 10.1007/s40495-015-0022-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
100 Tsuchiya S, Oku M, Imanaka Y, Kunimoto R, Okuno Y, Terasawa K, Sato F, Tsujimoto G, Shimizu K. MicroRNA-338-3p and microRNA-451 contribute to the formation of basolateral polarity in epithelial cells. Nucleic Acids Res. 2009;37:3821-3827. [PMID: 19386621 DOI: 10.1093/nar/gkp255] [Cited by in Crossref: 53] [Cited by in F6Publishing: 53] [Article Influence: 4.1] [Reference Citation Analysis]
101 Iorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med. 2012;4:143-159. [PMID: 22351564 DOI: 10.1002/emmm.201100209] [Cited by in Crossref: 1001] [Cited by in F6Publishing: 942] [Article Influence: 100.1] [Reference Citation Analysis]
102 Zoon CK, Starker EQ, Wilson AM, Emmert-Buck MR, Libutti SK, Tangrea MA. Current molecular diagnostics of breast cancer and the potential incorporation of microRNA. Expert Rev Mol Diagn 2009;9:455-67. [PMID: 19580430 DOI: 10.1586/erm.09.25] [Cited by in Crossref: 39] [Cited by in F6Publishing: 28] [Article Influence: 3.0] [Reference Citation Analysis]
103 Miraghel SA, Ebrahimi N, Khani L, Mansouri A, Jafarzadeh A, Ahmadi A, Aref AR. Crosstalk between non-coding RNAs expression profile, drug resistance and immune response in breast cancer. Pharmacol Res 2021;:106041. [PMID: 34952200 DOI: 10.1016/j.phrs.2021.106041] [Reference Citation Analysis]
104 Wang Z, Liu L, Guo X, Guo C, Wang W. microRNA-1236-3p Regulates DDP Resistance in Lung Cancer Cells. Open Med (Wars) 2018;14:41-51. [PMID: 30805558 DOI: 10.1515/med-2019-0007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
105 Al-Khanbashi M, Caramuta S, Alajmi AM, Al-Haddabi I, Al-Riyami M, Lui WO, Al-Moundhri MS. Tissue and Serum miRNA Profile in Locally Advanced Breast Cancer (LABC) in Response to Neo-Adjuvant Chemotherapy (NAC) Treatment. PLoS One 2016;11:e0152032. [PMID: 27064979 DOI: 10.1371/journal.pone.0152032] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
106 Cui SY, Wang R, Chen LB. MicroRNAs: key players of taxane resistance and their therapeutic potential in human cancers. J Cell Mol Med 2013;17:1207-17. [PMID: 24106980 DOI: 10.1111/jcmm.12131] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
107 Duan Z, Gao Y, Shen J, Choy E, Cote G, Harmon D, Bernstein K, Lozano-Calderon S, Mankin H, Hornicek FJ. miR-15b modulates multidrug resistance in human osteosarcoma in vitro and in vivo. Mol Oncol 2017;11:151-66. [PMID: 28145098 DOI: 10.1002/1878-0261.12015] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
108 Pasquier J, Galas L, Boulangé-Lecomte C, Rioult D, Bultelle F, Magal P, Webb G, Le Foll F. Different modalities of intercellular membrane exchanges mediate cell-to-cell p-glycoprotein transfers in MCF-7 breast cancer cells. J Biol Chem 2012;287:7374-87. [PMID: 22228759 DOI: 10.1074/jbc.M111.312157] [Cited by in Crossref: 88] [Cited by in F6Publishing: 51] [Article Influence: 8.8] [Reference Citation Analysis]
109 Liang Z, Wu H, Xia J, Li Y, Zhang Y, Huang K, Wagar N, Yoon Y, Cho HT, Scala S, Shim H. Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem Pharmacol. 2010;79:817-824. [PMID: 19883630 DOI: 10.1016/j.bcp.2009.10.017] [Cited by in Crossref: 224] [Cited by in F6Publishing: 213] [Article Influence: 17.2] [Reference Citation Analysis]
110 Begicevic RR, Falasca M. ABC Transporters in Cancer Stem Cells: Beyond Chemoresistance. Int J Mol Sci. 2017;18. [PMID: 29117122 DOI: 10.3390/ijms18112362] [Cited by in Crossref: 132] [Cited by in F6Publishing: 128] [Article Influence: 26.4] [Reference Citation Analysis]
111 Jin L, Zhang N, Zhang Q, Ding G, Yang Z, Zhang Z. Serum microRNAs as potential new biomarkers for cisplatin resistance in gastric cancer patients. PeerJ 2020;8:e8943. [PMID: 32328349 DOI: 10.7717/peerj.8943] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
112 Fang Y, Shen H, Cao Y, Li H, Qin R, Chen Q, Long L, Zhu XL, Xie CJ, Xu WL. Involvement of miR-30c in resistance to doxorubicin by regulating YWHAZ in breast cancer cells. Braz J Med Biol Res 2014;47:60-9. [PMID: 24519092 DOI: 10.1590/1414-431X20133324] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
113 Zhao L, Wang Y, Jiang L, He M, Bai X, Yu L, Wei M. MiR-302a/b/c/d cooperatively sensitizes breast cancer cells to adriamycin via suppressing P-glycoprotein(P-gp) by targeting MAP/ERK kinase kinase 1 (MEKK1). J Exp Clin Cancer Res 2016;35:25. [PMID: 26842910 DOI: 10.1186/s13046-016-0300-8] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 8.3] [Reference Citation Analysis]
114 Kovalchuk O, Zemp FJ, Filkowski JN, Altamirano AM, Dickey JS, Jenkins-Baker G, Marino SA, Brenner DJ, Bonner WM, Sedelnikova OA. microRNAome changes in bystander three-dimensional human tissue models suggest priming of apoptotic pathways. Carcinogenesis. 2010;31:1882-1888. [PMID: 20643754 DOI: 10.1093/carcin/bgq119] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 3.8] [Reference Citation Analysis]
115 Sarkar FH, Li Y, Wang Z, Kong D, Ali S. Implication of microRNAs in drug resistance for designing novel cancer therapy. Drug Resist Updat 2010;13:57-66. [PMID: 20236855 DOI: 10.1016/j.drup.2010.02.001] [Cited by in Crossref: 148] [Cited by in F6Publishing: 126] [Article Influence: 12.3] [Reference Citation Analysis]
116 Zheng H, Liu Z, Liu T, Cai Y, Wang Y, Lin S, Chen J, Wang J, Wang Z, Jiang B. Fas signaling promotes chemoresistance in gastrointestinal cancer by up-regulating P-glycoprotein. Oncotarget 2014;5:10763-77. [PMID: 25333257 DOI: 10.18632/oncotarget.2498] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
117 Pigati L, Yaddanapudi SC, Iyengar R, Kim DJ, Hearn SA, Danforth D, Hastings ML, Duelli DM. Selective release of microRNA species from normal and malignant mammary epithelial cells. PLoS One. 2010;5:e13515. [PMID: 20976003 DOI: 10.1371/journal.pone.0013515] [Cited by in Crossref: 401] [Cited by in F6Publishing: 407] [Article Influence: 33.4] [Reference Citation Analysis]
118 Meng HT, Zhu L, Ni WM, You LS, Jin J, Qian WB. Triptolide inhibits the proliferation of cells from lymphocytic leukemic cell lines in association with downregulation of NF-κB activity and miR-16-1*. Acta Pharmacol Sin 2011;32:503-11. [PMID: 21441948 DOI: 10.1038/aps.2010.237] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
119 Singh R, Mo YY. Role of microRNAs in breast cancer. Cancer Biol Ther. 2013;14:201-212. [PMID: 23291983 DOI: 10.4161/cbt.23296] [Cited by in Crossref: 73] [Cited by in F6Publishing: 65] [Article Influence: 8.1] [Reference Citation Analysis]
120 Sharma S, Patnaik PK, Aronov S, Kulshreshtha R. ApoptomiRs of Breast Cancer: Basics to Clinics. Front Genet 2016;7:175. [PMID: 27746811 DOI: 10.3389/fgene.2016.00175] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
121 Usmani A, Shoro AA, Shirazi B, Memon Z. Investigative and extrapolative role of microRNAs' genetic expression in breast carcinoma. Pak J Med Sci 2016;32:766-72. [PMID: 27375730 DOI: 10.12669/pjms.323.9321] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
122 Koturbash I, Tolleson WH, Guo L, Yu D, Chen S, Hong H, Mattes W, Ning B. microRNAs as pharmacogenomic biomarkers for drug efficacy and drug safety assessment. Biomark Med 2015;9:1153-76. [PMID: 26501795 DOI: 10.2217/bmm.15.89] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 6.4] [Reference Citation Analysis]
123 Chen J, Shin VY, Siu MT, Ho JC, Cheuk I, Kwong A. miR-199a-5p confers tumor-suppressive role in triple-negative breast cancer. BMC Cancer 2016;16:887. [PMID: 27842518 DOI: 10.1186/s12885-016-2916-7] [Cited by in Crossref: 48] [Cited by in F6Publishing: 51] [Article Influence: 8.0] [Reference Citation Analysis]
124 Pan YZ, Morris ME, Yu AM. MicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cells. Mol Pharmacol. 2009;75:1374-1379. [PMID: 19270061 DOI: 10.1124/mol.108.054163] [Cited by in Crossref: 219] [Cited by in F6Publishing: 206] [Article Influence: 16.8] [Reference Citation Analysis]
125 Ardelt W, Ardelt B, Darzynkiewicz Z. Ribonucleases as potential modalities in anticancer therapy. Eur J Pharmacol 2009;625:181-9. [PMID: 19825371 DOI: 10.1016/j.ejphar.2009.06.067] [Cited by in Crossref: 79] [Cited by in F6Publishing: 71] [Article Influence: 6.1] [Reference Citation Analysis]
126 Liu H, Brannon AR, Reddy AR, Alexe G, Seiler MW, Arreola A, Oza JH, Yao M, Juan D, Liou LS, Ganesan S, Levine AJ, Rathmell WK, Bhanot GV. Identifying mRNA targets of microRNA dysregulated in cancer: with application to clear cell Renal Cell Carcinoma. BMC Syst Biol 2010;4:51. [PMID: 20420713 DOI: 10.1186/1752-0509-4-51] [Cited by in Crossref: 184] [Cited by in F6Publishing: 176] [Article Influence: 15.3] [Reference Citation Analysis]
127 Balbaied T, Moore E. Overview of Optical and Electrochemical Alkaline Phosphatase (ALP) Biosensors: Recent Approaches in Cells Culture Techniques. Biosensors (Basel) 2019;9:E102. [PMID: 31450819 DOI: 10.3390/bios9030102] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
128 do Imperio GE, Bloise E, Javam M, Lye P, Constantinof A, Dunk C, Dos Reis FM, Lye SJ, Gibb W, Ortiga-Carvalho TM, Matthews SG. Chorioamnionitis Induces a Specific Signature of Placental ABC Transporters Associated with an Increase of miR-331-5p in the Human Preterm Placenta. Cell Physiol Biochem 2018;45:591-604. [PMID: 29402780 DOI: 10.1159/000487100] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
129 Liang G, Zhu Y, Ali DJ, Tian T, Xu H, Si K, Sun B, Chen B, Xiao Z. Engineered exosomes for targeted co-delivery of miR-21 inhibitor and chemotherapeutics to reverse drug resistance in colon cancer. J Nanobiotechnology. 2020;18:10. [PMID: 31918721 DOI: 10.1186/s12951-019-0563-2] [Cited by in Crossref: 65] [Cited by in F6Publishing: 81] [Article Influence: 32.5] [Reference Citation Analysis]
130 Heß AK, Weichert W, Budach V, Tinhofer I. [The role of microRNAs in head and neck squamous cell carcinoma : Biomarkers for prognosis, therapy selection, and novel therapeutics]. HNO 2016;64:296-302. [PMID: 26746640 DOI: 10.1007/s00106-015-0111-9] [Reference Citation Analysis]
131 Holleman A, Chung I, Olsen RR, Kwak B, Mizokami A, Saijo N, Parissenti A, Duan Z, Voest EE, Zetter BR. miR-135a contributes to paclitaxel resistance in tumor cells both in vitro and in vivo. Oncogene. 2011;30:4386-4398. [PMID: 21552288 DOI: 10.1038/onc.2011.148] [Cited by in Crossref: 78] [Cited by in F6Publishing: 74] [Article Influence: 7.1] [Reference Citation Analysis]
132 Sriraman SK, Aryasomayajula B, Torchilin VP. Barriers to drug delivery in solid tumors. Tissue Barriers. 2014;2:e29528. [PMID: 25068098 DOI: 10.4161/tisb.29528] [Cited by in Crossref: 140] [Cited by in F6Publishing: 126] [Article Influence: 17.5] [Reference Citation Analysis]
133 Turdo A, Porcelli G, D'Accardo C, Franco SD, Verona F, Forte S, Giuffrida D, Memeo L, Todaro M, Stassi G. Metabolic Escape Routes of Cancer Stem Cells and Therapeutic Opportunities. Cancers (Basel) 2020;12:E1436. [PMID: 32486505 DOI: 10.3390/cancers12061436] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
134 Aung TN, Qu Z, Kortschak RD, Adelson DL. Understanding the Effectiveness of Natural Compound Mixtures in Cancer through Their Molecular Mode of Action. Int J Mol Sci 2017;18:E656. [PMID: 28304343 DOI: 10.3390/ijms18030656] [Cited by in Crossref: 116] [Cited by in F6Publishing: 100] [Article Influence: 23.2] [Reference Citation Analysis]
135 Kochan DZ, Ilnytskyy Y, Golubov A, Deibel SH, McDonald RJ, Kovalchuk O. Circadian disruption-induced microRNAome deregulation in rat mammary gland tissues. Oncoscience 2015;2:428-42. [PMID: 26097876 DOI: 10.18632/oncoscience.157] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
136 Xiao Z, Chen S, Feng S, Li Y, Zou J, Ling H, Zeng Y, Zeng X. Function and mechanisms of microRNA-20a in colorectal cancer. Exp Ther Med 2020;19:1605-16. [PMID: 32104211 DOI: 10.3892/etm.2020.8432] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
137 Raychaudhuri M, Bronger H, Buchner T, Kiechle M, Weichert W, Avril S. MicroRNAs miR-7 and miR-340 predict response to neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 2017;162:511-21. [PMID: 28181130 DOI: 10.1007/s10549-017-4132-9] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 6.2] [Reference Citation Analysis]
138 Wang X, Zhu J. Mir-1307 regulates cisplatin resistance by targeting Mdm4 in breast cancer expressing wild type P53. Thorac Cancer 2018;9:676-83. [PMID: 29697201 DOI: 10.1111/1759-7714.12607] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
139 Ruggeri C, Gioffré S, Achilli F, Colombo GI, D'Alessandra Y. Role of microRNAs in doxorubicin-induced cardiotoxicity: an overview of preclinical models and cancer patients. Heart Fail Rev 2018;23:109-22. [PMID: 28944400 DOI: 10.1007/s10741-017-9653-0] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 14.3] [Reference Citation Analysis]
140 Pan Y, Zhang F, Zhao Y, Shao D, Zheng X, Chen Y, He K, Li J, Chen L. Berberine Enhances Chemosensitivity and Induces Apoptosis Through Dose-orchestrated AMPK Signaling in Breast Cancer. J Cancer 2017;8:1679-89. [PMID: 28775788 DOI: 10.7150/jca.19106] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 9.4] [Reference Citation Analysis]
141 Madurantakam Royam M, Ramesh R, Shanker R, Sabarimurugan S, Kumarasamy C, Ramesh N, Gothandam KM, Baxi S, Gupta A, Krishnan S, Jayaraj R. miRNA Predictors of Pancreatic Cancer Chemotherapeutic Response: A Systematic Review and Meta-Analysis. Cancers (Basel) 2019;11:E900. [PMID: 31252688 DOI: 10.3390/cancers11070900] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
142 Jin L, Ma XM, Wang TT, Yang Y, Zhang N, Zeng N, Bai ZG, Yin J, Zhang J, Ding GQ, Zhang ZT. Psoralen Suppresses Cisplatin-Mediated Resistance and Induces Apoptosis of Gastric Adenocarcinoma by Disruption of the miR196a-HOXB7-HER2 Axis. Cancer Manag Res 2020;12:2803-27. [PMID: 32368152 DOI: 10.2147/CMAR.S248094] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
143 Wang H, Huang C, Zhao L, Zhang H, Yang JM, Luo P, Zhan BX, Pan Q, Li J, Wang BL. Histone deacetylase inhibitors regulate P-gp expression in colorectal cancer via transcriptional activation and mRNA stabilization. Oncotarget 2016;7:49848-58. [PMID: 27409663 DOI: 10.18632/oncotarget.10488] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
144 Moitra K. Overcoming Multidrug Resistance in Cancer Stem Cells. Biomed Res Int. 2015;2015:635745. [PMID: 26649310 DOI: 10.1155/2015/635745] [Cited by in Crossref: 79] [Cited by in F6Publishing: 79] [Article Influence: 11.3] [Reference Citation Analysis]
145 Amorim M, Salta S, Henrique R, Jerónimo C. Decoding the usefulness of non-coding RNAs as breast cancer markers. J Transl Med 2016;14:265. [PMID: 27629831 DOI: 10.1186/s12967-016-1025-3] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 5.5] [Reference Citation Analysis]
146 Hayes EL, Lewis-Wambi JS. Mechanisms of endocrine resistance in breast cancer: an overview of the proposed roles of noncoding RNA. Breast Cancer Res 2015;17:40. [PMID: 25849966 DOI: 10.1186/s13058-015-0542-y] [Cited by in Crossref: 104] [Cited by in F6Publishing: 106] [Article Influence: 14.9] [Reference Citation Analysis]
147 Hu C, Yu M, Ren Y, Li K, Maggio DM, Mei C, Ye L, Wei J, Jin J, Zhuang Z, Tong H. PP2A inhibition from LB100 therapy enhances daunorubicin cytotoxicity in secondary acute myeloid leukemia via miR-181b-1 upregulation. Sci Rep 2017;7:2894. [PMID: 28588271 DOI: 10.1038/s41598-017-03058-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
148 Hu J, Fang Y, Cao Y, Qin R, Chen Q. miR-449a Regulates proliferation and chemosensitivity to cisplatin by targeting cyclin D1 and BCL2 in SGC7901 cells. Dig Dis Sci. 2014;59:336-345. [PMID: 24248414 DOI: 10.1007/s10620-013-2923-3] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 5.0] [Reference Citation Analysis]
149 Fassan M, Baffa R, Palazzo JP, Lloyd J, Crosariol M, Liu CG, Volinia S, Alder H, Rugge M, Croce CM. MicroRNA expression profiling of male breast cancer. Breast Cancer Res. 2009;11:R58. [PMID: 19664288 DOI: 10.1186/bcr2348] [Cited by in Crossref: 81] [Cited by in F6Publishing: 84] [Article Influence: 6.2] [Reference Citation Analysis]
150 Raza U, Zhang JD, Sahin O. MicroRNAs: master regulators of drug resistance, stemness, and metastasis. J Mol Med (Berl). 2014;92:321-336. [PMID: 24509937 DOI: 10.1007/s00109-014-1129-2] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 5.5] [Reference Citation Analysis]
151 Wang Z, Ji F. Downregulation of microRNA-17-5p inhibits drug resistance of gastric cancer cells partially through targeting p21. Oncol Lett. 2018;15:4585-4591. [PMID: 29541229 DOI: 10.3892/ol.2018.7822] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
152 Kwok GT, Zhao JT, Weiss J, Mugridge N, Brahmbhatt H, MacDiarmid JA, Robinson BG, Sidhu SB. Translational applications of microRNAs in cancer, and therapeutic implications. Noncoding RNA Res 2017;2:143-50. [PMID: 30159433 DOI: 10.1016/j.ncrna.2017.12.002] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]
153 Xia W, Liu Y, Du Y, Cheng T, Hu X, Li X. MicroRNA-423 Drug Resistance and Proliferation of Breast Cancer Cells by Targeting ZFP36. Onco Targets Ther 2020;13:769-82. [PMID: 32158228 DOI: 10.2147/OTT.S217745] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
154 Wang W, Zhang L, Wang Y, Ding Y, Chen T, Wang Y, Wang H, Li Y, Duan K, Chen S, Yang Q, Chen C. Involvement of miR-451 in resistance to paclitaxel by regulating YWHAZ in breast cancer. Cell Death Dis 2017;8:e3071. [PMID: 28981108 DOI: 10.1038/cddis.2017.460] [Cited by in Crossref: 52] [Cited by in F6Publishing: 58] [Article Influence: 10.4] [Reference Citation Analysis]
155 Feng F, Zhu X, Wang C, Chen L, Cao W, Liu Y, Chen Q, Xu W. Downregulation of hypermethylated in cancer-1 by miR-4532 promotes adriamycin resistance in breast cancer cells. Cancer Cell Int 2018;18:127. [PMID: 30202238 DOI: 10.1186/s12935-018-0616-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
156 Mazan-Mamczarz K, Gartenhaus RB. Role of microRNA deregulation in the pathogenesis of diffuse large B-cell lymphoma (DLBCL). Leuk Res 2013;37:1420-8. [PMID: 24054860 DOI: 10.1016/j.leukres.2013.08.020] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 3.6] [Reference Citation Analysis]
157 Vasconcelos FC, de Souza PS, Hancio T, de Faria FCC, Maia RC. Update on drug transporter proteins in acute myeloid leukemia: Pathological implication and clinical setting. Crit Rev Oncol Hematol 2021;160:103281. [PMID: 33667660 DOI: 10.1016/j.critrevonc.2021.103281] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
158 Gisel A, Valvano M, El Idrissi IG, Nardulli P, Azzariti A, Carrieri A, Contino M, Colabufo NA. miRNAs for the detection of multidrug resistance: overview and perspectives. Molecules 2014;19:5611-23. [PMID: 24786846 DOI: 10.3390/molecules19055611] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
159 Lin J, Jiang J, Zhou R, Li X, Ye J. MicroRNA-451b Participates in Coronary Heart Disease By Targeting VEGFA. Open Med (Wars) 2018;15:1-7. [PMID: 31922013 DOI: 10.1515/med-2020-0001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
160 Antoon JW, Nitzchke AM, Martin EC, Rhodes LV, Nam S, Wadsworth S, Salvo VA, Elliott S, Collins-Burow B, Nephew KP. Inhibition of p38 mitogen-activated protein kinase alters microRNA expression and reverses epithelial-to-mesenchymal transition. Int J Oncol. 2013;42:1139-1150. [PMID: 23403951 DOI: 10.3892/ijo.2013.1814] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.2] [Reference Citation Analysis]
161 Danza K, Silvestris N, Simone G, Signorile M, Saragoni L, Brunetti O, Monti M, Mazzotta A, De Summa S, Mangia A, Tommasi S. Role of miR-27a, miR-181a and miR-20b in gastric cancer hypoxia-induced chemoresistance. Cancer Biol Ther. 2016;17:400-406. [PMID: 26793992 DOI: 10.1080/15384047.2016.1139244] [Cited by in Crossref: 48] [Cited by in F6Publishing: 46] [Article Influence: 9.6] [Reference Citation Analysis]
162 Liu F, Di Wang X. miR-150-5p represses TP53 tumor suppressor gene to promote proliferation of colon adenocarcinoma. Sci Rep 2019;9:6740. [PMID: 31043658 DOI: 10.1038/s41598-019-43231-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
163 Ingelman-Sundberg M, Zhong XB, Hankinson O, Beedanagari S, Yu AM, Peng L, Osawa Y. Potential role of epigenetic mechanisms in the regulation of drug metabolism and transport. Drug Metab Dispos 2013;41:1725-31. [PMID: 23918665 DOI: 10.1124/dmd.113.053157] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 6.1] [Reference Citation Analysis]
164 Bao L, Hazari S, Mehra S, Kaushal D, Moroz K, Dash S. Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298. Am J Pathol 2012;180:2490-503. [PMID: 22521303 DOI: 10.1016/j.ajpath.2012.02.024] [Cited by in Crossref: 158] [Cited by in F6Publishing: 149] [Article Influence: 15.8] [Reference Citation Analysis]
165 Zangouei AS, Moghbeli M. MicroRNAs as the critical regulators of cisplatin resistance in gastric tumor cells. Genes Environ 2021;43:21. [PMID: 34099061 DOI: 10.1186/s41021-021-00192-4] [Reference Citation Analysis]
166 Zhao H, Ardelt B, Ardelt W, Shogen K, Darzynkiewicz Z. The cytotoxic ribonuclease onconase targets RNA interference (siRNA). Cell Cycle 2008;7:3258-61. [PMID: 18927512 DOI: 10.4161/cc.7.20.6855] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 2.3] [Reference Citation Analysis]
167 Abdi J, Jian H, Chang H. Role of micro-RNAs in drug resistance of multiple myeloma. Oncotarget 2016;7:60723-35. [PMID: 27494872 DOI: 10.18632/oncotarget.11032] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 6.5] [Reference Citation Analysis]
168 Chen PS, Su JL, Hung MC. Dysregulation of microRNAs in cancer. J Biomed Sci 2012;19:90. [PMID: 23075324 DOI: 10.1186/1423-0127-19-90] [Cited by in Crossref: 92] [Cited by in F6Publishing: 81] [Article Influence: 9.2] [Reference Citation Analysis]
169 Deng X, Zuo M, Pei Z, Xie Y, Yang Z, Zhang Z, Jiang M, Kuang D. MicroRNA-455-5p Contributes to Cholangiocarcinoma Growth and Mediates Galangin's Anti-Tumor Effects. J Cancer 2021;12:4710-21. [PMID: 34149934 DOI: 10.7150/jca.58873] [Reference Citation Analysis]
170 Miricescu D, Totan A, Stanescu-Spinu II, Badoiu SC, Stefani C, Greabu M. PI3K/AKT/mTOR Signaling Pathway in Breast Cancer: From Molecular Landscape to Clinical Aspects. Int J Mol Sci 2020;22:E173. [PMID: 33375317 DOI: 10.3390/ijms22010173] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
171 Tormo E, Ballester S, Adam-Artigues A, Burgués O, Alonso E, Bermejo B, Menéndez S, Zazo S, Madoz-Gúrpide J, Rovira A, Albanell J, Rojo F, Lluch A, Eroles P. The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factors. Sci Rep 2019;9:5316. [PMID: 30926829 DOI: 10.1038/s41598-019-41472-y] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 10.3] [Reference Citation Analysis]
172 Yu S, Wei Y, Xu Y, Zhang Y, Li J, Zhang J. Extracellular vesicles in breast cancer drug resistance and their clinical application. Tumour Biol 2016;37:2849-61. [PMID: 26797784 DOI: 10.1007/s13277-015-4683-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
173 Guancial EA, Chowdhury D, Rosenberg JE. Personalized therapy for urothelial cancer: review of the clinical evidence. Clin Investig (Lond) 2011;1:546-55. [PMID: 22754656 DOI: 10.4155/cli.11.26] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
174 Biersack B. Current state of phenolic and terpenoidal dietary factors and natural products as non-coding RNA/microRNA modulators for improved cancer therapy and prevention. Noncoding RNA Res 2016;1:12-34. [PMID: 30159408 DOI: 10.1016/j.ncrna.2016.07.001] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
175 To KK, Robey RW, Knutsen T, Zhan Z, Ried T, Bates SE. Escape from hsa-miR-519c enables drug-resistant cells to maintain high expression of ABCG2. Mol Cancer Ther. 2009;8:2959-2968. [PMID: 19825807 DOI: 10.1158/1535-7163.mct-09-0292] [Cited by in Crossref: 79] [Cited by in F6Publishing: 38] [Article Influence: 6.6] [Reference Citation Analysis]
176 Yin Y, Wang X, Li T, Ren Q, Li L, Sun X, Zhang B, Wang X, Han H, He Y, Cao Z, Sun X, Zhou Z. MicroRNA-221 promotes breast cancer resistance to adriamycin via modulation of PTEN/Akt/mTOR signaling. Cancer Med 2020;9:1544-52. [PMID: 31899608 DOI: 10.1002/cam4.2817] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
177 Chen YR, Li HN, Zhang LJ, Zhang C, He JG. Protein Arginine Methyltransferase 5 Promotes Esophageal Squamous Cell Carcinoma Proliferation and Metastasis via LKB1/AMPK/mTOR Signaling Pathway. Front Bioeng Biotechnol 2021;9:645375. [PMID: 34124017 DOI: 10.3389/fbioe.2021.645375] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
178 Wang Z, Li Y, Ahmad A, Azmi AS, Kong D, Banerjee S, Sarkar FH. Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance. Drug Resist Updat 2010;13:109-18. [PMID: 20692200 DOI: 10.1016/j.drup.2010.07.001] [Cited by in Crossref: 237] [Cited by in F6Publishing: 230] [Article Influence: 19.8] [Reference Citation Analysis]
179 Chernyy V, Pustylnyak V, Kozlov V, Gulyaeva L. Increased expression of miR-155 and miR-222 is associated with lymph node positive status. J Cancer 2018;9:135-40. [PMID: 29290778 DOI: 10.7150/jca.22181] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
180 Ren Y, Zhou X, Mei M, Yuan XB, Han L, Wang GX, Jia ZF, Xu P, Pu PY, Kang CS. MicroRNA-21 inhibitor sensitizes human glioblastoma cells U251 (PTEN-mutant) and LN229 (PTEN-wild type) to taxol. BMC Cancer. 2010;10:27. [PMID: 20113523 DOI: 10.1186/1471-2407-10-27] [Cited by in Crossref: 137] [Cited by in F6Publishing: 129] [Article Influence: 11.4] [Reference Citation Analysis]
181 Rodrigues AC, Li X, Radecki L, Pan YZ, Winter JC, Huang M, Yu AM. MicroRNA expression is differentially altered by xenobiotic drugs in different human cell lines. Biopharm Drug Dispos. 2011;32:355-367. [PMID: 21796641 DOI: 10.1002/bdd.764] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 3.4] [Reference Citation Analysis]
182 Su CM, Wang MY, Hong CC, Chen HA, Su YH, Wu CH, Huang MT, Chang YW, Jiang SS, Sung SY, Chang JY, Chen LT, Chen PS, Su JL. miR-520h is crucial for DAPK2 regulation and breast cancer progression. Oncogene 2016;35:1134-42. [PMID: 25982274 DOI: 10.1038/onc.2015.168] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 4.3] [Reference Citation Analysis]
183 Gabra MM, Salmena L. microRNAs and Acute Myeloid Leukemia Chemoresistance: A Mechanistic Overview. Front Oncol 2017;7:255. [PMID: 29164055 DOI: 10.3389/fonc.2017.00255] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 6.6] [Reference Citation Analysis]
184 Zangouei AS, Alimardani M, Moghbeli M. MicroRNAs as the critical regulators of Doxorubicin resistance in breast tumor cells. Cancer Cell Int 2021;21:213. [PMID: 33858435 DOI: 10.1186/s12935-021-01873-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
185 Buhagiar A, Ayers D. Chemoresistance, cancer stem cells, and miRNA influences: the case for neuroblastoma. Anal Cell Pathol (Amst). 2015;2015:150634. [PMID: 26258008 DOI: 10.1155/2015/150634] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
186 Li N, Yang L, Wang H, Yi T, Jia X, Chen C, Xu P. MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells. PLoS One 2015;10:e0128886. [PMID: 26043084 DOI: 10.1371/journal.pone.0128886] [Cited by in Crossref: 50] [Cited by in F6Publishing: 55] [Article Influence: 7.1] [Reference Citation Analysis]
187 Liu Z, Miao T, Feng T, Jiang Z, Li M, Zhou L, Li H. miR-451a Inhibited Cell Proliferation and Enhanced Tamoxifen Sensitive in Breast Cancer via Macrophage Migration Inhibitory Factor. Biomed Res Int 2015;2015:207684. [PMID: 26161389 DOI: 10.1155/2015/207684] [Cited by in Crossref: 9] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
188 Wang R, Chen DQ, Huang JY, Zhang K, Feng B, Pan BZ, Chen J, De W, Chen LB. Acquisition of radioresistance in docetaxel-resistant human lung adenocarcinoma cells is linked with dysregulation of miR-451/c-Myc-survivin/rad-51 signaling. Oncotarget 2014;5:6113-29. [PMID: 25026294 DOI: 10.18632/oncotarget.2176] [Cited by in Crossref: 16] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
189 Iorio MV, Croce CM. microRNA involvement in human cancer. Carcinogenesis 2012;33:1126-33. [PMID: 22491715 DOI: 10.1093/carcin/bgs140] [Cited by in Crossref: 375] [Cited by in F6Publishing: 371] [Article Influence: 37.5] [Reference Citation Analysis]
190 Xing Z, Wang X, Liu J, Liu G, Zhang M, Feng K, Wang X. Effect of MiR-210 on the Chemosensitivity of Breast Cancer by Regulating JAK-STAT Signaling Pathway. Biomed Res Int 2021;2021:7703159. [PMID: 34423038 DOI: 10.1155/2021/7703159] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
191 Iorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med. 2012;4:143-159. [PMID: 22351564 DOI: 10.1007/978-1-62703-547-7_14] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
192 Lindner K, Eichelmann AK, Matuszcak C, Hussey DJ, Haier J, Hummel R. Complex Epigenetic Regulation of Chemotherapy Resistance and Biohlogy in Esophageal Squamous Cell Carcinoma via MicroRNAs. Int J Mol Sci 2018;19:E499. [PMID: 29414899 DOI: 10.3390/ijms19020499] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
193 Zhang N, Hu G, Myers TG, Williamson PR. Protocols for the Analysis of microRNA Expression, Biogenesis, and Function in Immune Cells. Curr Protoc Immunol 2019;126:e78. [PMID: 31483103 DOI: 10.1002/cpim.78] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
194 Sotillo E, Thomas-Tikhonenko A. Shielding the messenger (RNA): microRNA-based anticancer therapies. Pharmacol Ther. 2011;131:18-32. [PMID: 21514318 DOI: 10.1016/j.pharmthera.2011.04.006] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 4.0] [Reference Citation Analysis]
195 Devaney E, Winter AD, Britton C. microRNAs: a role in drug resistance in parasitic nematodes? Trends Parasitol 2010;26:428-33. [PMID: 20541972 DOI: 10.1016/j.pt.2010.05.003] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 2.9] [Reference Citation Analysis]
196 Gregory LA, Ricart RA, Patel SA, Lim PK, Rameshwar P. microRNAs, Gap Junctional Intercellular Communication and Mesenchymal Stem Cells in Breast Cancer Metastasis. Curr Cancer Ther Rev. 2011;7:176-183. [PMID: 21886602 DOI: 10.2174/157339411796234915] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
197 Ao X, Nie P, Wu B, Xu W, Zhang T, Wang S, Chang H, Zou Z. Decreased expression of microRNA-17 and microRNA-20b promotes breast cancer resistance to taxol therapy by upregulation of NCOA3. Cell Death Dis 2016;7:e2463. [PMID: 27831559 DOI: 10.1038/cddis.2016.367] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 5.8] [Reference Citation Analysis]
198 Ng EK, Li R, Shin VY, Jin HC, Leung CP, Ma ES, Pang R, Chua D, Chu KM, Law WL. Circulating microRNAs as specific biomarkers for breast cancer detection. PLoS One. 2013;8:e53141. [PMID: 23301032 DOI: 10.1371/journal.pone.0053141] [Cited by in Crossref: 164] [Cited by in F6Publishing: 156] [Article Influence: 18.2] [Reference Citation Analysis]
199 Lo PK, Wolfson B, Zhou X, Duru N, Gernapudi R, Zhou Q. Noncoding RNAs in breast cancer. Brief Funct Genomics 2016;15:200-21. [PMID: 26685283 DOI: 10.1093/bfgp/elv055] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
200 Mehrgou A, Akouchekian M. Therapeutic impacts of microRNAs in breast cancer by their roles in regulating processes involved in this disease. J Res Med Sci 2017;22:130. [PMID: 29387117 DOI: 10.4103/jrms.JRMS_967_16] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 4.4] [Reference Citation Analysis]
201 Ozawa PMM, Alkhilaiwi F, Cavalli IJ, Malheiros D, de Souza Fonseca Ribeiro EM, Cavalli LR. Extracellular vesicles from triple-negative breast cancer cells promote proliferation and drug resistance in non-tumorigenic breast cells. Breast Cancer Res Treat 2018;172:713-23. [PMID: 30173296 DOI: 10.1007/s10549-018-4925-5] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 8.5] [Reference Citation Analysis]
202 To KK. MicroRNA: a prognostic biomarker and a possible druggable target for circumventing multidrug resistance in cancer chemotherapy. J Biomed Sci 2013;20:99. [PMID: 24358977 DOI: 10.1186/1423-0127-20-99] [Cited by in Crossref: 42] [Cited by in F6Publishing: 46] [Article Influence: 4.7] [Reference Citation Analysis]
203 Ng EK, Wong CL, Ma ES, Kwong A. MicroRNAs as New Players for Diagnosis, Prognosis, and Therapeutic Targets in Breast Cancer. J Oncol. 2009;2009:305420. [PMID: 19644558 DOI: 10.1155/2009/305420] [Cited by in Crossref: 14] [Cited by in F6Publishing: 21] [Article Influence: 1.1] [Reference Citation Analysis]
204 Brenner B, Hoshen MB, Purim O, David MB, Ashkenazi K, Marshak G, Kundel Y, Brenner R, Morgenstern S, Halpern M, Rosenfeld N, Chajut A, Niv Y, Kushnir M. MicroRNAs as a potential prognostic factor in gastric cancer. World J Gastroenterol 2011; 17(35): 3976-3985 [PMID: 22046085 DOI: 10.3748/wjg.v17.i35.3976] [Cited by in CrossRef: 67] [Cited by in F6Publishing: 62] [Article Influence: 6.1] [Reference Citation Analysis]
205 Cox J, Weinman S. Mechanisms of doxorubicin resistance in hepatocellular carcinoma. Hepat Oncol. 2016;3:57-59. [PMID: 26998221 DOI: 10.2217/hep.15.41] [Cited by in Crossref: 57] [Cited by in F6Publishing: 61] [Article Influence: 9.5] [Reference Citation Analysis]
206 Xue H, Yu Z, Liu Y, Yuan W, Yang T, You J, He X, Lee RJ, Li L, Xu C. Delivery of miR-375 and doxorubicin hydrochloride by lipid-coated hollow mesoporous silica nanoparticles to overcome multiple drug resistance in hepatocellular carcinoma. Int J Nanomedicine. 2017;12:5271-5287. [PMID: 28769563 DOI: 10.2147/ijn.s135306] [Cited by in Crossref: 37] [Cited by in F6Publishing: 14] [Article Influence: 7.4] [Reference Citation Analysis]
207 Kasiappan R, Rajarajan D. Role of MicroRNA Regulation in Obesity-Associated Breast Cancer: Nutritional Perspectives. Adv Nutr 2017;8:868-88. [PMID: 29141971 DOI: 10.3945/an.117.015800] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
208 Yang Z, Liu Z. The Emerging Role of MicroRNAs in Breast Cancer. J Oncol 2020;2020:9160905. [PMID: 32714393 DOI: 10.1155/2020/9160905] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
209 Melo SA, Esteller M. A precursor microRNA in a cancer cell nucleus: get me out of here! Cell Cycle 2011;10:922-5. [PMID: 21346411 DOI: 10.4161/cc.10.6.15119] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 2.7] [Reference Citation Analysis]
210 Peng J, Wang W, Hua S, Liu L. Roles of Extracellular Vesicles in Metastatic Breast Cancer. Breast Cancer (Auckl) 2018;12:1178223418767666. [PMID: 29881285 DOI: 10.1177/1178223418767666] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
211 Mishra PJ. The miRNA-drug resistance connection: a new era of personalized medicine using noncoding RNA begins. Pharmacogenomics 2012;13:1321-4. [PMID: 22966880 DOI: 10.2217/pgs.12.121] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
212 Haenisch S, Werk AN, Cascorbi I. MicroRNAs and their relevance to ABC transporters. Br J Clin Pharmacol 2014;77:587-96. [PMID: 24645868 DOI: 10.1111/bcp.12251] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 6.4] [Reference Citation Analysis]
213 Si W, Shen J, Zheng H, Fan W. The role and mechanisms of action of microRNAs in cancer drug resistance. Clin Epigenetics. 2019;11:25. [PMID: 30744689 DOI: 10.1186/s13148-018-0587-8] [Cited by in Crossref: 146] [Cited by in F6Publishing: 149] [Article Influence: 48.7] [Reference Citation Analysis]
214 Xia RB, Wang HY, Dai D, Dong TM, Wang HP, Zou SL, Zhang J. MiR-128-3p increases sensitivity of hepatoma cells to oxaliplatin by targeting Lin28B. Shijie Huaren Xiaohua Zazhi 2018; 26(30): 1748-1757 [DOI: 10.11569/wcjd.v26.i30.1748] [Reference Citation Analysis]
215 Jayaraj R, Nayagam SG, Kar A, Sathyakumar S, Mohammed H, Smiti M, Sabarimurugan S, Kumarasamy C, Priyadharshini T, Gothandam KM, Ramesh N, Gupta A, Baxi S, Swamiappan S, Krishnan S. Clinical Theragnostic Relationship between Drug-Resistance Specific miRNA Expressions, Chemotherapeutic Resistance, and Sensitivity in Breast Cancer: A Systematic Review and Meta-Analysis. Cells 2019;8:E1250. [PMID: 31615089 DOI: 10.3390/cells8101250] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
216 Miao Y, Zheng W, Li N, Su Z, Zhao L, Zhou H, Jia L. MicroRNA-130b targets PTEN to mediate drug resistance and proliferation of breast cancer cells via the PI3K/Akt signaling pathway. Sci Rep 2017;7:41942. [PMID: 28165066 DOI: 10.1038/srep41942] [Cited by in Crossref: 90] [Cited by in F6Publishing: 96] [Article Influence: 18.0] [Reference Citation Analysis]
217 Hagiwara K, Gailhouste L, Yasukawa K, Kosaka N, Ochiya T. A robust screening method for dietary agents that activate tumour-suppressor microRNAs. Sci Rep 2015;5:14697. [PMID: 26423775 DOI: 10.1038/srep14697] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
218 Li X, Pan YZ, Seigel GM, Hu ZH, Huang M, Yu AM. Breast cancer resistance protein BCRP/ABCG2 regulatory microRNAs (hsa-miR-328, -519c and -520h) and their differential expression in stem-like ABCG2+ cancer cells. Biochem Pharmacol 2011;81:783-92. [PMID: 21219875 DOI: 10.1016/j.bcp.2010.12.018] [Cited by in Crossref: 75] [Cited by in F6Publishing: 72] [Article Influence: 6.8] [Reference Citation Analysis]
219 Chen J, Tian W, Cai H, He H, Deng Y. Down-regulation of microRNA-200c is associated with drug resistance in human breast cancer. Med Oncol 2012;29:2527-34. [PMID: 22101791 DOI: 10.1007/s12032-011-0117-4] [Cited by in Crossref: 90] [Cited by in F6Publishing: 83] [Article Influence: 8.2] [Reference Citation Analysis]
220 Jiang F, Zhao W, Zhou L, Liu Z, Li W, Yu D. MiR-222 targeted PUMA to improve sensitization of UM1 cells to cisplatin. Int J Mol Sci 2014;15:22128-41. [PMID: 25474084 DOI: 10.3390/ijms151222128] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
221 Ogawa D, Ansari K, Nowicki MO, Salińska E, Bronisz A, Godlewski J. MicroRNA-451 Inhibits Migration of Glioblastoma while Making It More Susceptible to Conventional Therapy. Noncoding RNA 2019;5:E25. [PMID: 30875963 DOI: 10.3390/ncrna5010025] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
222 Majumder S, Jacob ST. Emerging role of microRNAs in drug-resistant breast cancer. Gene Expr. 2011;15:141-151. [PMID: 22268296 DOI: 10.3727/105221611x13176664479287] [Cited by in Crossref: 33] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]